犬类中，血管肉瘤是一种相对常见的恶性肿瘤，也是金毛寿命研究中的主要结果之一。该研究收集一组金毛寻回犬的纵向数据和样本，旨在识别营养、遗传、环境、生活方式和繁殖等风险因素，以及狗类癌症和其他重要疾病的发生。本分析描述了可供研究人员使用的逐渐积累的数据和样本，以实现该研究的目标。截至2022年9月，共有3044只参加该研究的狗中，233只被诊断为血管肉瘤（7.65%），发病率为每100狗年1.10例。内脏性血管肉瘤是最常见的类型，影响了211只（6.9%）。其中，128例内脏性血管肉瘤诊断显示有脾肿瘤（占60.7%），而119例显示有心脏肿瘤（占56.4%）。未被诊断为血管肉瘤的概率从大约4岁时的100%逐渐下降，到12岁时的概率分别为：未绝育雌性91.1%（95% CI 84.4%-98.3%），绝育雌性60.7%（95% CI 41.6%-88.6%），未绝育雄性72.9%（95% CI 62.9%-84.6%），绝育雄性70.0%（95% CI 53.4%-92.0%）。内脏性血管肉瘤的1年生存概率为1.42%（95% CI 0.37%-5.47%），皮肤血管肉瘤的1年生存概率为84.6%（95% CI 67.1%-99.99%）。这些积累的数据和样本对于进一步研究犬类血管肉瘤具有重要意义，并有潜在的转化医学作用。© 2023 John Wiley & Sons Ltd.

Haemangiosarcoma is a relatively common malignant tumour in dogs, and one of the primary outcomes of interest for the Golden Retriever Lifetime Study. This study collects longitudinal data and samples from a cohort of golden retrievers, with the aim of identification of nutritional, genetic, environmental, lifestyle and reproductive risk factors for cancers and other important diseases in dogs. This analysis describes the accumulating data and samples, which are available for use by researchers to fulfil the study's objectives. As of September 2022, 233/3044 dogs enrolled in the study had been diagnosed with haemangiosarcoma (7.65%), with an incidence rate of 1.10 cases per 100 dog-years. Visceral haemangiosarcoma was the most common, affecting 211/3044 study dogs (6.9%). One hundred and twenty eight visceral haemangiosarcoma diagnoses specified the presence of splenic tumours (60.7%) and 119 specified the presence of cardiac tumours (56.4%). The probability of remaining without a haemangiosarcoma diagnosis declined from 100% from approximately 4 years of age, to a 12 year probability of 91.1% in intact females (95% CI 84.4%-98.3%), 60.7% in neutered females (95% CI 41.6%-88.6%), 72.9% in intact males (95% CI 62.9%-84.6%) and 70.0% in neutered males (95% CI 53.4%-92.0%). The 1 year survival probability for visceral haemangiosarcoma was 1.42% (95% CI 0.37%-5.47%); for cutaneous haemangiosarcoma, it was 84.6% (95% CI 67.1%-99.99%). The accumulated data and samples are a considerable resource for further investigation of canine haemangiosarcoma and have a potential role in translational medicine.© 2023 John Wiley & Sons Ltd.